نمایش پرونده ساده آیتم

dc.contributor.authorEsmaili, H
dc.contributor.authorMostafidi, E
dc.contributor.authorMehramuz, B
dc.contributor.authorArdalan, M
dc.contributor.authorMohajel-Shoja, M
dc.date.accessioned2018-08-26T08:34:08Z
dc.date.available2018-08-26T08:34:08Z
dc.date.issued2016
dc.identifier10.12860/jnp.2016.02
dc.identifier.urihttp://dspace.tbzmed.ac.ir:8080/xmlui/handle/123456789/52513
dc.description.abstractContext: Hemophagocytic syndrome (HPS) is mainly characterized by massive infiltration of bone marrow by activated macrophages and often presents with pancytopenia. Thrombotic microangiopathy (TMA) is also present with thrombocytopenia and renal involvement. Both conditions could coexist with each other and complicate the condition. Evidence Acquisition: Directory of Open Access Journals (DOAJ), EMBASE, Google Scholar, PubMed, EBSCO, and Web of Science with keywords relevant to; Hemophagocytic syndrome, macrophage activation syndrome, interferon-gamma and thrombotic microangiopathy, have been searched. Results: Viral infection, rheumatologic disease and malignancies are the main underlying causes for secondary HPS. calcineurin inhibitors and viral infections are also the main underlying causes of TMA in transplant recipients. In this review, we discussed a 39-year-old male who presented with pancytopenia and renal allograft dysfunction. With the diagnosis of HPS induced TMA his renal condition and pancytopenia improved after receiving intravenous immunoglobulin (IVIG) and plasmapheresis therapy. Conclusions: HPS is an increasingly recognized disorder in the realm of different medical specialties. Renal involvement complicates the clinical picture of the disease, and this condition even is more complex in renal transplant recipients. We should consider the possibility of HPS in any renal transplant recipient with pancytopenia and allograft dysfunction. The combination of HPS with TMA future increases the complexity of the situation. آ© 2016 The Author(s).
dc.language.isoEnglish
dc.relation.ispartofJournal of Nephropathology
dc.subjectbasiliximab
dc.subjectcalcineurin inhibitor
dc.subjectfresh frozen plasma
dc.subjectimmunoglobulin
dc.subjectlactate dehydrogenase
dc.subjectmycophenolate mofetil
dc.subjectprednisolone
dc.subjectrecombinant interleukin 1 receptor blocking agent
dc.subjectrituximab
dc.subjecttacrolimus
dc.subjectthymocyte antibody
dc.subjecttocilizumab
dc.subjectanemia
dc.subjectArticle
dc.subjectblood analysis
dc.subjectbone marrow biopsy
dc.subjectcreatinine blood level
dc.subjectdifferential diagnosis
dc.subjectfever
dc.subjecthemolytic uremic syndrome
dc.subjecthuman
dc.subjecthuman tissue
dc.subjectimmunosuppressive treatment
dc.subjectkidney
dc.subjectmacrophage activation syndrome
dc.subjectmalignant neoplastic disease
dc.subjectmicroscopy
dc.subjectmortality
dc.subjectpancytopenia
dc.subjectplasmapheresis
dc.subjectproteinuria
dc.subjectrenal graft dysfunction
dc.subjectrheumatic disease
dc.subjectthrombocyte count
dc.subjectthrombotic thrombocytopenic purpura
dc.subjectvirus infection
dc.subjectweakness
dc.titleAn update on renal involvement in hemophagocytic syndrome (macrophage activation syndrome)
dc.typeArticle
dc.citation.volume5
dc.citation.issue1
dc.citation.spage8
dc.citation.epage14
dc.citation.indexScopus
dc.identifier.DOIhttps://doi.org/10.12860/jnp.2016.02


فایلهای درون آیتم

Thumbnail

این آیتم در مجموعه های زیر مشاهده می شود

نمایش پرونده ساده آیتم